	STPE	6
	UL 1 1 2005	14 JU
ATEN	* THADEMARY	8/

î

PATENT 2801-0209X cop {

IN THE U.S. PATENT AND TRADEMARK OFFICE

Patentee: Malcolm Carter et al.

Patent No.: 6,713,485 B2

Issue Date: March 30, 2004

For: HETEROCYCLIC COMPOUNDS

Certificate 'JUL 1 8 2005 of Correction

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

CERTIFICATE OF CORRECTIONS BRANCH

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 July 11, 2005

Sir:

ATTN:

Attached hereto is a Certificate of Correction (Form PTO-1050) in connection with the above-identified patent.

It is noted that the attached Certificate of Correction form is being filed to correct various printing and typographical errors in the patent. These errors are either printing errors made by the USPTO upon printing of the patent or are typographical errors that occurred in good faith, and do not involve new matter, and should not require a re-examination.

A detailed listing of the corrected errors is as follows.

 On page 1, left column of the patent, under the field identified as "(*) Notice" - the notice that the patent is subject to a terminal disclaimer is missing.

2) At various places throughout the patent the 07/12/2005 \$\$ITHIB1 00000025 6713485

01 FC:1811

U.S.Patent No. 6,713,485 B

tyrosine kinase "Lck" has been misprinted as "Ick".

- 3) Column 1, line 46, "eg" has been replaced with --e.g.--.
- 4) Column 10, line 48, "fu ran-2-yl)" has been replaced with --furan-2-yl)--.
- 5) Column 18, line 33, "thiazol-2-y)" has been replaced with --thiazol-2-yl)--.
- 6) Column 23, line 36, "[5-(I[2-(methanesulphonyl)" has been replaced with --[5-({[2-(methanesulphonyl)--.
- 7) Column 36, lines 29 and 64 and column 37, line 29, "tic" has been replaced with --tlc--.
- 8) Column 38, line 59, "(α -bromoketone" has been replaced with -- α -bromoketone--.
- 9) A space has been inserted approximately between lines 32 and 33 of column 50.
- 10) Column 53, line 31, "2-to (tributylstannyl)" has been replaced with --2-(tributylstannyl)--.
- 11) A space has been inserted between lines 62 and 63 of column 54.
- 12) Column 59, line 61, "(4-(3-Fluorobenzyl oxy)" has been replaced with --(4-(3-Fluorobenzyloxy)--.
- 13) Column 67, line 37, "N-{4-[(3bromobenzyl)oxy]phenyl}-6-[5-(J[2-" has been replaced with --N-{4-[(3-bromobenzyl)oxy]phenyl}-6-[5-({[2---



U.S.Patent No. 6,713,485 B

14) Column 75, line 20, "Phenyzsulphonylphenylamino)"
has been replaced with

--Phenylsulphonylphenylamino)--.

- 15) Column 76, line 13, "g-phosphate" has been replaced with $--\gamma$ -phosphate--.
- 16) Claims 1, 7, and 13 "and salts or solvates" has been replaced with --or salts or solvates--.

The above corrections address printing and typographical errors. The fee under 37 C.F.R. § 1.20(a) of \$100.00 is attached hereto.

Please charge any fees or credit any overpayment pursuant to 37 C.F.R. § 1.20 to Deposit Account No. 02-2448.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By <u>Mac</u> MaryAnne Armstrong, #40,069

P.O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000

2801-0209X

Attachment(s)

PTO/SB/44 (08-00)

X

Approved for use through 6/30/99. OMB 0651-0033

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,713,485 B2

DATED : March 30, 2004

INVENTOR(S): Malcolm Carter et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 1, left column, in field (*), insert the following:

--The portion of the term of this patent subsequent to January 8, 2019 has been disclaimed--

Column 1, line 22; column 2, lines 6, 9, 35, and 37; column 4, lines 25 and 31; and column 33, lines 44 and 54, in each indicated instance, replace "Ick" with --lck--

Column 1, line 46, replace "eg" with --e.g.--

Column 10, line 48, replace "fu ran-2-yl)" --furan-2yl)--

Column 18, line 33, replace "thiazol-2-y)" with --thiazol-2-yl)--

Column 23, line 36, replace "[5-(I[2-(methanesulphonyl))/=-

Column 36, lines 29 and 64 and column 37, line 29 replace with "tic" --tlc--

Column 38, line 59, replace "(α -bromoketone" with -- α -bromoketone--

Column 50, approximately between line 32, i.e. immediately after "5.20 (s, 2H); MS m/z 490 (M+1)" and line 33, i.e. immediately before "6-Iodo-(4-(3-fluorobenzyloxy)-3-methoxyphenyl)-quinazolin-4yl)amine", insert a space.

Column 53, line 31, replace "2-to (tributylstannyl)"
with --2-(tributylstannyl)--

Column 54, between lines 62 and 63, insert a space

Column 59, line 61, replace "(4-(3-Fluorobenzyl oxy)" with -- (4-(3-Fluorobenzyloxy) --Column 67, line 37, replace $N-{4-[(3-bromobenzy1)oxy]pheny1}-6-[5-(J[2-" with$ --N-{4-[(3-bromobenzyl)oxy]phenyl}-6-[5-({[2---Column 20, 75, line replace "Phenyzsulphonylphenylamino)" with --Phenylsulphonylphenylamino)--Column 76, line 13, replace "g-phosphate" with --y-phosphate--Claims 1, 7, and 13 replace "and salts or solvates" with --or salts or solvates--

 τ_{i}

MAILING ADDRESS OF SENDER: 2801-0209X -MAA/MAA BIRCH, STEWART, KOLASCH & BIRCH, LLP **PTO BOX 16X** PATENT NO. 6,713,485 B2

No. of Additional copies

- 0

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLTED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

21

¢

PATENT NO. : 6,713,485 B2 Page 1 of 2 DATED : March 30, 2004 INVENTOR(S) : Malcolm Carter et al. It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below: Title page, Item [*] Notice, insert the following: -- The portion of the term of this patent subsequent to January 8, 2019 has been disclaimed --. Column 1. Line 22, replace "Ick" with -- 1ck --. Line 46, replace "eg" with -- e.g. --. Column 2, Lines 6, 9, 35 and 37, replace "Ick" with -- 1ck --. Column 4, Lines 25 and 31, replace "Ick" with -- 1ck" Column 10, Line 48, replace "fu ran-2-yl)" with -- furan-2-yl) --. Column 18, Line 33, replace "thiazol-2-y)" with -- thiazol-2-yl) --. Column 23, Line 36, replace "[5-(I[2-(methanesulphonyl)" with -- [5-({[2-(methanesulphonyl) --Column 33, Lines 44 and 54, replace "Ick" with -- 1ck --. Column 36, Lines 29 and 64, replace "tic" with -- tlc --. Column 37, Line 29, replace "tic" with -- tlc --. Column 38, Line 59, replace "(a-bromoketone" with -- a-bromoketone --. Column 50, Lines 32 and 33, immediately after "5.20 (s, 2H); MS m/z 490 (M+1)" and immediately before "6-Iodo-(4-(3-fluorobenzyloxy)-3-methoxyphenyl)-quinazolin-4yl)amine", insert a space.